Is Sanofi Consumer Healthcare India Overvalued or Undervalued Right Now?

Is Sanofi Consumer Healthcare India overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 4,092.00, the stock trades roughly 23.6% below its 52 week high of Rs 5,357.00 and about 2.9% above its 52 week low of Rs 3,975.00.

Sanofi Consumer Healthcare India's share price moved down 1.11% in the latest session to Rs 4,092.00, against a market capitalisation of Rs 9,491 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple, and works through the full Sanofi Consumer Healthcare India overvalued or undervalued picture step by step.

Click Here – Get Free Investment Predictions

Sanofi Consumer Healthcare India Overvalued or Undervalued: Valuation Metrics

Valuation Metric	Sanofi Consumer Healthcare India
CMP (2 Sep 2026)	Rs 4,092.00
Market Cap	Rs 9,491 Cr
P/E Ratio	35.68
Industry P/E	51.38
P/B Ratio	27.28
Sector Average P/B (pharmaceutical and consumer health)	7.31
Return on Equity (ROE)	76.46%
Sector Average ROE (pharmaceutical and consumer health)	12.94%
EPS (TTM)	Rs 115.50
Book Value per Share	Rs 151.07
Debt to Equity	0.06
Dividend Yield	1.82%
Sector Average Dividend Yield (pharmaceutical and consumer health)	0.30%
52 Week High / Low	Rs 5,357.00 / Rs 3,975.00

The headline number here is the price to earnings ratio. At 35.68, the Sanofi Consumer Healthcare India PE ratio is 0.69 times the industry average of 51.38. Measured against its pharmaceutical and consumer health sector peers, the gap widens further on other measures too: a P/B of 27.28 against a sector average of 7.31, and an ROE of 76.46% against a sector average of 12.94%. This table alone is not enough to settle whether Sanofi Consumer Healthcare India overvalued or undervalued is the fair read, but it is the starting point for the rest of this analysis.

Is Sanofi Consumer Healthcare India Overvalued or Undervalued Based on Its P/E Ratio?

Based on the P/E ratio alone, Sanofi Consumer Healthcare India looks undervalued. The stock's PE of 35.68 sits well below the industry average of 51.38, which can reflect either a genuine bargain or a market discounting some risk in the business that is not obvious from the ratio itself. Investors relying only on the PE ratio would classify Sanofi Consumer Healthcare India as cheaper than its peers, but the Sanofi Consumer Healthcare India PE ratio still needs to be read alongside its return ratios and earnings quality before calling Sanofi Consumer Healthcare India overvalued or undervalued on this measure alone.

Check Sanofi Consumer Healthcare India's Live Fundamentals on the Univest Screener

Sanofi Consumer Healthcare India's Financial Growth and Profitability

Detailed multi-year revenue and profit figures were not available for Sanofi Consumer Healthcare India at the time of writing, so this section relies on the metrics that are confirmed: a return on equity of 76.46%, an EPS of Rs 115.50, and a book value of Rs 151.07 per share. Readers should treat the Sanofi Consumer Healthcare India overvalued or undervalued call here as based on current ratios rather than a multi-year earnings trend, since a single year of ROE and EPS data is a narrower base to work from than a full revenue and profit history would be. That is worth keeping in mind when weighing how much confidence to place in the current PE of 35.68 relative to the industry average of 51.38.

Download the Univest iOS App or Univest Android App to track Sanofi Consumer Healthcare India's live share price and valuation ratios.

Sanofi Consumer Healthcare India Overvalued or Undervalued: The Case for Overvalued

Before getting to the bullet points, it helps to frame the Sanofi Consumer Healthcare India overvalued or undervalued question in terms of what would make the bear case right.

• Rich price to book: A P/B of 27.28 is well above the sector average of 7.31.
• Limited margin of safety: At Rs 4,092.00, the stock is only 23.6% below its 52 week high of Rs 5,357.00, leaving less room for error if earnings disappoint.

Sanofi Consumer Healthcare India Overvalued or Undervalued: The Case Against It

The other side of the Sanofi Consumer Healthcare India overvalued or undervalued debate rests on the quality metrics below.

• High return on equity: ROE of 76.46% against a sector average of 12.94% reflects efficient use of shareholder capital.
• Low leverage: A debt to equity ratio of 0.06 gives Sanofi Consumer Healthcare India a comparatively strong balance sheet.
• Reasonable income: A dividend yield of 1.82% offers some cushion while the market decides on the growth story.
• 52 week range context: At Rs 4,092.00, the stock is 2.9% above its 52 week low of Rs 3,975.00, showing it has already found some support at lower levels.

Verdict: Is Sanofi Consumer Healthcare India Overvalued or Undervalued Right Now?

On balance, Sanofi Consumer Healthcare India looks undervalued by traditional multiples, trading at a PE of 35.68 against an industry average of 51.38. That gap can close either through the share price catching up or through the business underperforming enough to justify the discount, so the read depends on which explanation fits the company's recent earnings trend better. A 76.46% ROE is a reasonable starting point for that judgement, but investors should weigh why the market has kept the stock at a discount before treating the gap as a straightforward opportunity. On the specific question of Sanofi Consumer Healthcare India overvalued or undervalued, the multiples currently point one way even if the fundamentals soften that read.

What Could Change Whether Sanofi Consumer Healthcare India Is Overvalued or Undervalued?

Two broad scenarios could shift this valuation call on Sanofi Consumer Healthcare India in either direction. On the upside, the market recognising the gap between the PE of 35.68 and the industry average of 51.38, which would show up as the share price re-rating higher without a change in earnings. On the downside, a genuine deterioration in the business that justifies the current discount, in which case the low PE would turn out to be a fair reflection of risk rather than a bargain. Investors watching the Sanofi Consumer Healthcare India share price over the next few quarters should track whether reported ROE holds near 76.46% and whether the PE gap versus the industry average of 51.38 widens or narrows, since both will matter more to the eventual answer on Sanofi Consumer Healthcare India overvalued or undervalued than the current price point on its own.

Conclusion

Sanofi Consumer Healthcare India's numbers point to a stock that is undervalued on headline multiples, though its return ratios help explain part of the gap. Investors tracking the Sanofi Consumer Healthcare India share price should watch whether earnings growth can keep pace with the current PE of 35.68, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. For anyone still weighing Sanofi Consumer Healthcare India overvalued or undervalued as a one-line takeaway, the multiples say undervalued while the return ratios offer partial support for the current price. This article is for informational purposes only and is not investment advice.

Sanofi Consumer Healthcare India Overvalued or Undervalued: FAQs

Is Sanofi Consumer Healthcare India overvalued or undervalued right now?

Ans. Based on a PE ratio of 35.68 against an industry average of 51.38, Sanofi Consumer Healthcare India currently looks undervalued on relative valuation. Its 76.46% ROE is an important part of the Sanofi Consumer Healthcare India overvalued or undervalued picture alongside the PE ratio.

What is Sanofi Consumer Healthcare India's current PE ratio?

Ans. Sanofi Consumer Healthcare India's price to earnings ratio stands at 35.68, compared with an industry average PE of 51.38. This PE gap is the main input into the Sanofi Consumer Healthcare India overvalued or undervalued call made in this article.

What is Sanofi Consumer Healthcare India's return on equity?

Ans. Sanofi Consumer Healthcare India generates a return on equity of 76.46%, against a sector average of 12.94% among pharmaceutical and consumer health peers.

What is Sanofi Consumer Healthcare India's 52 week high and low?

Ans. Sanofi Consumer Healthcare India's 52 week high is Rs 5,357.00 and its 52 week low is Rs 3,975.00. The stock currently trades around Rs 4,092.00, roughly 23.6% below its high.

Does Sanofi Consumer Healthcare India have high debt?

Ans. Sanofi Consumer Healthcare India carries a debt to equity ratio of 0.06, which is low for its sector.

What is Sanofi Consumer Healthcare India's dividend yield?

Ans. Sanofi Consumer Healthcare India offers a dividend yield of 1.82% at the current share price.

Is Sanofi Consumer Healthcare India a good stock to buy at current levels?

Ans. Sanofi Consumer Healthcare India's current valuation suits investors who agree with the undervalued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.

What is Sanofi Consumer Healthcare India's price to book ratio?

Ans. Sanofi Consumer Healthcare India trades at a price to book ratio of 27.28, compared with a sector average of 7.31 among pharmaceutical and consumer health peers.

What is the simplest way to summarise Sanofi Consumer Healthcare India overvalued or undervalued?

Ans. On PE alone, Sanofi Consumer Healthcare India is undervalued against its industry average of 51.38. Layer in the 76.46% ROE and the answer to Sanofi Consumer Healthcare India overvalued or undervalued becomes more nuanced than the headline multiple suggests on its own.